Beijing, China

Kelong Fan

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 5.3

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2019-2023

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Kelong Fan: Innovator in Nanoscale Drug Delivery Systems

Introduction

Kelong Fan is a prominent inventor based in Beijing, China. He has made significant contributions to the field of drug delivery systems, particularly in developing nanoscale carriers that can effectively target brain lesions. With a total of 2 patents, his work is paving the way for advancements in treating neurodegenerative diseases and brain tumors.

Latest Patents

Kelong Fan's latest patents include a nanoscale drug carrier capable of passing through the blood-brain barrier. This innovative carrier is designed to target brain lesions, such as brain tumors or other neurodegenerative diseases. The drug carrier utilizes receptor-mediated transcytosis to cross the blood-brain barrier, providing an effective solution for treatment. Another notable patent is a tumor-specific targeted drug delivery system, which comprises a tumor-targeted drug carrier made from full heavy-chain human ferritin. This system allows for the binding of tumor-treating drugs to the carrier, enhancing the effectiveness of the treatment.

Career Highlights

Throughout his career, Kelong Fan has worked with esteemed organizations such as the Chinese Academy of Sciences and Kunshan Xinyunda Biotech Co., Ltd. His experience in these institutions has contributed to his expertise in the field of biotechnology and drug delivery systems.

Collaborations

Kelong Fan has collaborated with notable colleagues, including Xiyun Yan and Minmin Liang. These partnerships have fostered innovation and development in his research endeavors.

Conclusion

Kelong Fan's work in nanoscale drug delivery systems represents a significant advancement in medical technology. His innovative patents and collaborations highlight his commitment to improving treatment options for patients with brain-related conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…